- Home
- EQS vs LEXX Comparison
EQS vs LEXX Comparison
Compare EQS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- LEXX
- Stock Information
- Founded
- EQS 1991
- LEXX 2004
- Country
- EQS United States
- LEXX Canada
- Employees
- EQS N/A
- LEXX N/A
- Industry
- EQS Finance Companies
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- LEXX Health Care
- Exchange
- EQS Nasdaq
- LEXX Nasdaq
- Market Cap
- EQS 19.0M
- LEXX 19.6M
- IPO Year
- EQS N/A
- LEXX N/A
- Fundamental
- Price
- EQS $1.43
- LEXX $0.98
- Analyst Decision
- EQS
- LEXX Strong Buy
- Analyst Count
- EQS 0
- LEXX 1
- Target Price
- EQS N/A
- LEXX $5.00
- AVG Volume (30 Days)
- EQS 8.3K
- LEXX 131.4K
- Earning Date
- EQS 01-01-0001
- LEXX 07-14-2025
- Dividend Yield
- EQS N/A
- LEXX N/A
- EPS Growth
- EQS N/A
- LEXX N/A
- EPS
- EQS N/A
- LEXX N/A
- Revenue
- EQS $1,329,000.00
- LEXX $615,923.00
- Revenue This Year
- EQS N/A
- LEXX $6.04
- Revenue Next Year
- EQS N/A
- LEXX $8.36
- P/E Ratio
- EQS N/A
- LEXX N/A
- Revenue Growth
- EQS 152.66
- LEXX 49.85
- 52 Week Low
- EQS $0.74
- LEXX $0.79
- 52 Week High
- EQS $1.52
- LEXX $4.38
- Technical
- Relative Strength Index (RSI)
- EQS 61.15
- LEXX 55.13
- Support Level
- EQS $1.42
- LEXX $0.82
- Resistance Level
- EQS $1.43
- LEXX $1.05
- Average True Range (ATR)
- EQS 0.02
- LEXX 0.06
- MACD
- EQS -0.01
- LEXX 0.02
- Stochastic Oscillator
- EQS 75.00
- LEXX 70.77
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.